Journal of Diabetes Investigation (Jan 2020)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

  • Kazunori Utsunomiya,
  • Masayuki Senda,
  • Seigo Kakiuchi,
  • Hiroyuki Kameda,
  • Masahiro Tamura,
  • Yuji Kurihara,
  • Ryoji Gunji,
  • Shoko Fujii,
  • Kohei Kaku

DOI
https://doi.org/10.1111/jdi.13097
Journal volume & issue
Vol. 11, no. 1
pp. 132 – 141

Abstract

Read online

Abstract Aims/Introduction Due to the paucity of tofogliflozin data, we assessed the safety and effectiveness of tofogliflozin among Japanese patients with type 2 diabetes mellitus in the clinical setting, stratifying the patients by age, sex, estimated glomerular filtration (eGFR) rate and body mass index. We report the results of a 12‐month interim analysis. Materials and Methods This was a 3‐year prospective, observational and multicenter post‐marketing study (Japanese Study of tofogliflozin with type 2 diabetes mellitus Patients/Long Term). Results Out of 6,897 patients enrolled, the safety and effectiveness analysis populations consisted of 6,712 and 6,449 patients, respectively. During 12 months, adverse drug reactions and their incidence were 9.12 and 0.88%, respectively. The incidence of hypoglycemia was 0.67%. Polyuria/pollakiuria occurred more frequently in patients aged ≥65 years than in patients aged <65 years. Women experienced higher rates of urinary tract and genital infection than men. The lowest eGFR subgroup experienced maximum volume depletion‐related events. Cardiovascular and cerebrovascular disorders occurred in 0.55% of the patients. Glycated hemoglobin (HbA1c) and bodyweight significantly decreased by −0.76% and −2.73 kg, respectively, from baseline to the last observation carried forward (P < 0.0001). Except for the lowest eGFR subgroup, other eGFR subgroups showed significantly decreased HbA1c values. All eGFR subgroups showed significantly decreased bodyweight, and all body mass index subgroups showed significantly decreased HbA1c and bodyweight. Conclusions Our interim 12‐month data suggest that tofogliflozin could be used safely and effectively in Japanese patients with type 2 diabetes mellitus, as tofogliflozin was well tolerated with low hypoglycemia risk, and significantly improved HbA1c and bodyweight.

Keywords